The present study emphasizes, for the first time, the ability of KISIMA-Mash2 cancer vaccine to induce both antibodies and T cell immune response against a self-antigen, presumably due to the predicted MHC class I- and class II-presented epitopes in Mash2 with potential to stimulate both CD8+ and CD4+ T cells, respectively. The gene discussed is CD8A; the disease is cancer.